Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03250546

Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem Cell Transplant — ALTERGREF  

Hematopoietic Stem Cell Transplant Clinical Trial

Official title:
Randomized Prospective Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of GVHD in Haploidentical and HLA-9/10 Mismatched Unrelated Donors Hematopoietic Stem Cell Transplant

Clinical Trial Summary

The primary objective of this study is to compare the 2-year progression free survival without acute graft versus host disease (GvHD) (aGvHD) grade III-IV or without moderate or severe chronic (cGVHD) after transplant from haploidentical hematopoietic stell cell transplant (HSCT) or from an unrelated Human Leukocyte Antigen (HLA)-9/10 mismatched unrelated donor (MMUD).

It will use a Phase II, multicenter, prospective, randomized clinical trial.

By setting a power of 80% and a type I error rate of 5% for a two-sided log-rank test (hypotheses tested: probability of event-free survival at 2 years 50% vs. 30 %), 92 patients need to be recruited in each arm, for a total of 184 patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Hematopoietic Stem Cell Transplant
Clinical Trial Details
NCT number NCT03250546
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact
Status Recruiting
Phase Phase 2
Start date November 20, 2017
Completion date November 30, 2022
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT02451462 - Pilot Trial of Zoledronic Acid to Prevent Bone Loss in Hematopoietic Cell Transplant Recipients N/A
Terminated NCT01215981 - Influenza Vaccine Post Allogeneic Transplant N/A
Recruiting NCT03613532 - Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN Phase 1
Completed NCT01337648 - Radiation Biodosimetry in Children Undergoing Total Body Irradiation N/A
Recruiting NCT02982902 - T Cell Therapy of Opportunistic Cytomegalovirus Infection Early Phase 1
Completed NCT02441075 - 70% Ethanol for Decontamination of CVL Exposed to Calcineurine Inhibitors Version 1.0, 1/9/2014 N/A
Completed NCT04549038 - Time Restricted Nutrition in Pediatric Stem Cell Transplant Recipients N/A
Completed NCT03886909 - Impact of Prehabilitation in Oncology Via Exercise- Bone Marrow Transplant N/A
Not yet recruiting NCT05722210 - Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant
Not yet recruiting NCT06328127 - Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors N/A
Completed NCT03509051 - Prospective Study on the Vaccine Response to Meningococcal B Vaccine After Allogeneic Stem Cell Transplantation N/A
Terminated NCT02350777 - T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation Phase 2
Completed NCT04853277 - Patient Reported Outcomes and Patient Education in Cellular Therapy Patients N/A
Completed NCT03378089 - Music Therapy and Hematopoietic Stem Cell Transplant N/A
Completed NCT03039257 - Vitamin A Replacement in Patients Undergoing HSCT and Its Role on MBI-LCBI Rates N/A
Completed NCT03202849 - A Randomized Trial of Vitamin D Supplementation With or Without Vitamin A in Stem Cell Transplantation N/A
Completed NCT01504152 - International Travel Patterns and Health Preparations of Hematopoietic Stem Cell Transplant Recipients at Memorial Sloan-Kettering Cancer Center N/A
Completed NCT01581164 - Studies of the Immune Response to Vaccination After Hematopoietic Stem Cell Transplantation N/A
Completed NCT03759262 - Ultra-high Dose Vitamin D for HSCT Phase 1
Recruiting NCT04263597 - Oral Supplementation of 2'-Fucosyllactose in Allogeneic Bone Marrow Transplant Recipients Phase 1/Phase 2